(Bloomberg) -- GSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi, must face trials over whether...
-- GSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi , must face trials over whether the former heartburn treatment Zantac causes cancer.Oil Swings After OPEC+ Signals Plan to Return Barrels to Market
GSK is set to appeal the ruling, it said. The drugmaker emphasized that the decision “does not mean that the court agrees with plaintiffs’ experts’ scientific conclusions, and it does not determine liability.” GSK has consistently denied that Zantac causes cancer.
Zantac hit the US market as a prescription drug in 1983 before transforming into an over-the-counter heartburn treatment in 1995. GSK and Warner Lambert developed it as part of a joint venture, and the drug was owned by several companies through the years before Sanofi acquired it in 2017.Israel Seeks Underground Secrets by Tracking Cosmic Particles
A B.C. senior was surprised to find Canada’s largest advocacy association for older adults, the Canadian Association of Retired Persons , has teamed up with the world's biggest tobacco companies to convene a focus group about alternatives to cigarette smoking.Musician and actor Taylor Momsen is seemingly taking everything in stride after being bit by a bat while on stage in Spain last week.Patients lying shackled and blindfolded on more than a dozen beds inside a white tent in the desert.
Sanofi Heartburn Treatment Zantac GSK Plc
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GSK Plunges as Drugmaker Must Face Zantac Cases in DelawareGSK Plc shares slumped in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi, must face trials over whether the former heartburn treatment Zantac causes cancer.
Read more »
Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billionExplore stories from Atlantic Canada.
Read more »
Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billionExplore stories from Atlantic Canada.
Read more »
Indian drugmaker Cipla beats Q4 profit estimates on strong US demandExplore stories from Atlantic Canada.
Read more »
Drugmaker Abbott India posts Q4 profit rise on higher salesExplore stories from Atlantic Canada.
Read more »
Drugmaker Abbott India posts Q4 profit rise on higher salesExplore stories from Atlantic Canada.
Read more »